Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for TAK-279 Dose A, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for Apremilast, Otezla 10mg, 20mg, 30 mg film-coated tablets
TAK-279-PsA-3001
Phase 3 small_molecule active
Quick answer
Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for TAK-279 Dose A, ZASOCITINIB, ZASOCITINIB, Matching Placebo for TAK-279 Dose B, Otezla 10mg, 20mg, 30 mg film-coated tablets, Matching Placebo for Apremilast, Otezla 10mg, 20mg, 30 mg film-coated tablets for Psoriatic Arthritis is a Phase 3 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Psoriatic Arthritis
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active